Allergens present in the excretory/secretory (ES) products of adult Paragonimus ohirai were biochemically identified. Immunoblot analysis using sera from P. ohirai-infected rats revealed only two allergens to be major proteins in the ES products, with apparent molecular masses (Mr) of 27 and 29 kD. As the ES products contained a high proportion of acidic and neutral cysteine proteinases, we examined whether or not the allergens and the cysteine proteinases were identical. The acidic and neutral cysteine proteinases were biochemically purified from the ES products and showed Mr of 27 and 29 kD, respectively. The two cysteine proteinases had almost identical N-terminal amino acid sequences and were reactive with specific IgE in sera from the infected rats. The allergenicity of the cysteine proteinases was confirmed by 48-hour homologous passive cutaneous anaphylaxis. Immunoblot and immunocapture assays using anti-human IgE monoclonal antibody showed that the proteinase allergens were reactive with specific IgE of patients with paragonimiasis westermani. Also, the cysteine proteinases were reactive with specific IgG of both the infected rats and the patients. Therefore the acidic and neutral cysteine proteinases prepared from the ES products of P. ohirai will be useful allergens and antigens for the immunodiagnosis of paragonimiasis.

1.
Jarrett EE, Miller HRP: Production and activities of IgE in helminth infection. Prog Allergy 1982;31:178–233.
2.
Johansson SGO, Mellbin T, Vahlquist B: Immunoglobulin levels in Ethiopian preschool children with special reference to high concentrations of immunoglobulin E (IgND). Lancet 1968;i:1118–1121.
3.
Kojima S, Yokogawa M, Tada T: Raised levels of serum IgE in human helminthiases. Am J Trop Med Hyg 1972;21:913–918.
4.
Sadun EH: Homocytotropic antibody response to parasitic infections; in Soulsby EJL (ed): Immunity to Animal Parasites. New York, Academic Press, 1972, pp 97–129.
5.
Ikeda T, Tani S: Induction of secondary IgE antibody response in rats immunized with X-irradiated metacercariae of Paragonimus ohirai. Int Arch Allergy Appl Immunol 1988;85:213–218.
6.
Ikeda T, Oikawa Y, Owhashi M, Nawa Y: Parasite-specific IgE and IgG levels in the serum and pleural effusion of paragonimiasis westermani patients. Am J Trop Med Hyg 1992;47:104–107.
7.
Ikeda T, Oikawa Y, Owhashi M, Nawa Y: The localization of allergens of Paragonimus westermani by pleural exudates from patients. J Parasitol 1991;77:923–926.
8.
Ikeda T, Oikawa Y: Paragonimus ohirai: Immunobiochemical characterization on the tegumental glycocalyx of excysted juvenile recognized by a monoclonal antibody. Exp Parasitol 1991;72:252–261.
9.
Yamakami K: Purification and properties of a thiol protease from lung fluke adult Paragonimus ohirai. Comp Biochem Physiol B 1986;83:501–506.
10.
Yamakami K, Hamajima F: Purification and properties of a neutral thiol protease from larval trematode parasite Paragonimus westermani metacercariae. Comp Biochem Physiol B 1987;87:643–648.
11.
Ikeda T, Fujita K: IgE in Paragonimus ohirai-infected rats: Relationship between titer, migration route, and parasite age. J Parasitol 1980;66:197–204.
12.
Ikeda T: Protein A immunocapture assay detecting antibodies to fluke cysteine proteinases for immunodiagnosis of human paragonimiasis and fascioliasis. J Helminthol 2001;75:245–249.
13.
Yamamoto M, Yamakami K, Hamajima F: Cloning of a cDNA encoding a neutral thiol protease from Paragonimus westermani metacercariae. Mol Biochem Parasitol 1994;64:345–348.
14.
Kim TS, Na BK, Park PH, Song KJ, Hontzeas N, Song CY: Cloning and expression of a cysteine proteinase gene from Paragonimus westermani adult worms. J Parasitol 2000;86:333–339.
15.
Ottesen EA, Poindexter RW, Hussain R: Detection, quantitation, and specificity of antiparasite IgE antibodies in human schistosomiasis mansoni. Am J Trop Med Hyg 1981;30:1228–1237.
16.
Senft AW, Maddison SE: Hypersensitivity to parasite proteolytic enzyme in schistosomiasis. Am J Trop Med Hyg 1975;24:83–89.
17.
Dresden MH, Deelder AM: Schistosoma mansoni: Thiol proteinase properties of adult worm ‘hemoglobinase’. Exp Parasitol 1979;48:190–197.
18.
Chappell CL, Dresden MH: Schistosoma mansoni: Proteinase activity of ‘hemoglobinase’ from the digestive tract of adult worms. Exp Parasitol 1986;61:160–167.
19.
Ino Y, Ando T, Haida M, Nakamura K, Iwaki M, Okudaira H, Miyamoto T: Characterization of the proteases in the crude mite extract. Int Arch Allergy Appl Immunol 1989;89:321–326.
20.
Ando T, Ino Y, Haida M, Honma R, Maeda H, Yamakawa H, Iwaki M, Okudaira H: Isolation of cysteine protease in the crude mite extract, Dermatophagoides farinae. Int Arch Allergy Appl Immunol 1991;96:199–205.
21.
Ichikawa H, Ikeda T: Excretory/secretory antigens of adult Paragonimus ohirai recognized by a monoclonal antibody. Int J Parasitol 1995;25:725–730.
22.
Coles GC: Recent advances in schistosome biochemistry. Parasitology 1984;89:603–637.
23.
McKerrow JH, Doenhoff MJ: Schistosome proteinases. Parasitol Today 1988;4:334–340.
24.
Yokogawa M, Kojima S, Araki K, Tomioka H, Yosida S: Immunoglobulin E: Raised levels in sera and pleural exudates of patients with paragonimiasis. Am J Trop Med Hyg 1976;25:581–586.
25.
Hamajima F, Yamakami K, Fujino T: Localization of a thiol protease in metacercarial lung fluke. Jpn J Parasitol 1985;34:507–508.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.